Friday, July 10, 2026

Drug profile · INN

dinoprostone

dinoprostone (CERVIDIL) is a prostaglandin e2 receptor agonist. Route of administration: vaginal. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — dinoprostone
US status
approved
Class
Route
VAGINAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

dinoprostone (CERVIDIL) is a prostaglandin e2 receptor agonist. Route of administration: vaginal. Current US regulatory status: approved.

Key facts

INN dinoprostone
Brand CERVIDIL
Mechanism Prostaglandin E2 receptor agonist
Target Prostaglandin E2 receptor
Route VAGINAL
Formulation INSERT, EXTENDED RELEASE

Mechanism of action

Prostaglandin E2 receptor agonist

Primary target: Prostaglandin E2 receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. alprostadil Prostanoid EP1 receptor agonist
  2. misoprostol Prostanoid EP3 receptor agonist
  3. omidenepag isopropyl Prostanoid EP2 receptor agonist
  4. sepetaprost Prostanoid EP3 receptor agonist

Frequently asked questions

What is dinoprostone?

dinoprostone (CERVIDIL) is a prostaglandin e2 receptor agonist. Route of administration: vaginal. Current US regulatory status: approved.

What is the brand name for dinoprostone?

CERVIDIL is a marketed brand name for dinoprostone. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of dinoprostone?

dinoprostone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.